

Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 485 • October 2014

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Fortaz 2 g/Vial Injection (DIN 02212226), manufactured by GlaxoSmithKline, Ceftazidime 2 g/Vial Injection (DIN 00886955), manufactured by Pharmaceutical Partners of Canada Inc., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of September 29, 2014, all claims for Ceftazidime 2 g/Vial Injection (DIN 00886955) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter, this product will be subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations call centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)



®The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ABC 82320.485 2014/10